Faculty

Joseph H. Skalski, M.D.

Clinical Studies

Characterizing the Airway Mycobiome in Patients with Bronchiectasis Rochester, Minn.
The purpose of this study is to describe the airway mycobiome in patients with bronchiectasis and to identify microbial signatures associated with eosinophilic inflammation, as well as disease severity and control.
Prevalence of C. albicans and other dysbiosis associated intestinal fungal dysbiosis in patients with eosinophilic asthma and non-eosinophilic asthma Rochester, Minn.
The purpose of this study is to compare the gut bacterial and fungal microbiota profiles of patients with different asthma phenotypes (eosinophilic asthma and non-eosinophilic asthma).

Gut Microbiota Dysbiosis and Asthma Severity Rochester, Minn.
The purpose of this study is to compare the gut bacterial and fungal microbiota profiles of patients with poorly-controlled asthma and patients with well-controlled asthma.
Registry of Asthma Patients Initiating DUPIXENT® (RAPID) (RAPID) Rochester, Minn.
The purpose of this study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of patient demographics, and patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height). T

Additionally to characterize real-world use patterns, safety, and long-term effectiveness of DUPIXENT® for asthmam and to assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® .